Benjamin Walbaum, Medical Oncologist at Pontifical Catholic University of Chile, shared a post on LinkedIn:
“Breast Cancer Weekly, April 6–12, 2026
My takeaways from this week’s breast cancer data:
- Adjuvant Chemotherapy Outcomes in Older Adults With Nonmetastatic Triple-Negative Breast Cancer
JAMA Network Open
-In older patients with TNBC, adjuvant ChT was associated with better outcomes, especially in higher-risk disease. - Survival and Treatment Patterns in Stage III Inflammatory and Noninflammatory Breast Cancer
JAMA Network Open
-Inflammatory BC continues to have worse outcomes across all subtypes, and the declining use of trimodality therapy is concerning given its association with better survival. - Radiation Therapy Management in BRCA1/2 Carriers Diagnosed With Early Breast Cancer: An International Cohort Study
Radiotherapy and Oncology
-In young BRCA carriers, breast-conserving therapy did not worsen survival versus mastectomy, although it was associated with a higher risk of second primary breast events. - Hormone Therapy After Oophorectomy and Breast Cancer Risk in Women With BRCA Pathogenic Variant
JAMA Network Open
-Estrogen-only HRT after RRBO appears reassuring in BRCA carriers, particularly in BRCA1. - Association Between Asymptomatic Detection of Distant Metastases and Survival in BC: A Retrospective Cohort Study
BMC Women’s Health
-Asymptomatic detection of metastatic recurrence was associated with better post-metastatic survival. - PARP Inhibition with Olaparib and Talazoparib for HER2-negative Advanced Breast Cancer-Results from the Prospective Pregnant Registry
npj BC
-Real-world PARP inhibitor outcomes were consistent with pivotal trial data despite heavier pretreatment. - Treatment for Brain Metastases With Stereotactic Radiation vs Hippocampal-Avoidance Whole Brain Radiation
JAMA
-In patients with 5–20 brain metastases, stereotactic radiation improved symptom burden and daily functioning compared with HA-WBRT. - Neoadjuvant Palbociclib and Endocrine Therapy vs Chemotherapy in ER+/HER2− Breast Cancer: A Randomized Phase II Trial (PREDIX LumB)
Nature Communications
-The study was not positive for overall response superiority, but CDKPredX suggests that biomarker-guided selection may identify a subgroup more likely to benefit from palbociclib plus endocrine therapy. - Long-Term Prognostic Value of ctDNA in Early Breast Cancer: Insights From the Neoadjuvant ABCSG-34 Trial
npj BC
-Baseline ctDNA remains a promising long-term prognostic biomarker in early breast cancer, while the clinical role of ctDNA clearance still needs validation. - The Benefit of Adjuvant Pertuzumab and Trastuzumab According to Estrogen Receptor and HER2 Expression: A Sub-analysis of the APHINITY Trial
JNCI
-The benefit of pertuzumab may not be uniform across HER2-positive disease, but because this was a post-hoc subgroup analysis with negative interaction testing. - Advanced Triple-Negative Breast Cancer: Emerging Therapies and a Changing Treatment Landscape
ASCO Educational Book
-TROP2-directed ADCs are redefining the treatment landscape of advanced TNBC.”
Other Articles Featuring Benjamin Walbaum On OncoDaily.
